Paolo Tarantino: 40 Years of Antibody-Drug Conjugates at the 2026 EORTC-NCI-AACR Symposium
Paolo Tarantino/LinkedIn

Paolo Tarantino: 40 Years of Antibody-Drug Conjugates at the 2026 EORTC-NCI-AACR Symposium

Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, shared on LinkedIn:

“40 years of ADCs

An extraordinary journey, and we’re only at the beginning!

It was a privilege to speak at the Plenary Session on ADCs at the 2026 EORTC-NCI-AACR (ENA) Symposium in Barcelona.

In my presentation, I traced the remarkable 40-year evolution of ADCs as cancer therapies: from early concepts and decades of scientific challenges to the transformative therapies that are reshaping cancer treatment today.

Yet, the most exciting chapters of the ADC story are still ahead of us. With next-generation payloads, dual-payload, bispecific formats, and innovative conjugation technologies, we are only beginning to unlock the full potential of this drug class.

A pleasure to share the stage with Aditya Bardia, Raffaele Colombo, and Nicole Biber for an outstanding discussion on the present and future of ADCs.

Thank you to the EORTC, NCI, and AACR for the invitation and for bringing together such an inspiring scientific community!”

You can also read: